Shares in Dr Reddy's Laboratories fall 2.1 percent on worries the drug maker will post lower-than-expected October-December earnings, due later in the day
Shares in Dr Reddy's Laboratories
Margins are also expected to see significant erosion, several dealers add.
Dr Reddy's could miss consensus earnings per share (EPS) estimates by 6 percent in the October-December quarter, according to Thomson Reuters StarMine SmartEstimate data, which measures the forecasts from top-ranked analysts against wider forecasts. * StarMine SmartEstimate suggests EPS for the quarter ending December at Rs 26.03 compared with mean estimate of Rs 27.89.
Dr Reddys Labs stock price
On July 28, 2014, Dr Reddys Laboratories closed at Rs 2766.70, up Rs 20.85, or 0.76 percent. The 52-week high of the share was Rs 2939.80 and the 52-week low was Rs 2025.00.
The company's trailing 12-month (TTM) EPS was at Rs 113.47 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 24.38. The latest book value of the company is Rs 547.69 per share. At current value, the price-to-book value of the company is 5.05.
Set email alert for
ADS BY GOOGLE
video of the day
Positive on PSU banks; NPA cycle may have peaked: Barclays